Form 4: BIO-KEY International Director Cameron Williams Increases Stake Through Stock Grants

Cameron E. Williams, a Director at BIO-KEY International Inc., acquired 6,266 shares of common stock through restricted stock grants and compensation for board services, increasing his direct beneficial ownership to 21,950 shares.

Summary

• Cameron E. Williams, a Director of BIO-KEY INTERNATIONAL INC (BKYI), acquired a total of 6,266 shares of common stock on May 27, 2025.
• This includes 5,000 shares of Restricted Stock granted under the Issuer's 2023 Stock Incentive Plan.
• The 5,000 restricted shares will vest in three equal annual installments on each of the next three anniversaries of the grant date, contingent on continued service.
• An additional 1,266 shares were issued under the 2023 Stock Incentive Plan as payment for board committee meeting attendance fees.
• Following these transactions, Mr. Williams' direct beneficial ownership of BIO-KEY INTERNATIONAL INC common stock stands at 21,950 shares.

Sentiment

Score: 6

Explanation: The filing reports routine insider stock grants for a director, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. It's not a significant market-moving event but shows ongoing compensation practices.

Positives

• A director, Cameron E. Williams, increased his direct beneficial ownership in the company by 6,266 shares, signaling continued alignment with shareholder interests.
• The grants are part of the company's 2023 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• The shares were acquired at a price of $0, indicating they are grants for compensation rather than open market purchases, which might signal stronger conviction if purchased with personal capital.

Risks

• The vesting of 5,000 restricted shares is subject to the reporting person's continued employment or service to the Issuer, posing a risk of forfeiture if service ceases.

Future Outlook

The restricted stock granted to Director Cameron E. Williams is set to vest in three equal annual installments on each of the next three anniversaries of the grant date, contingent on his continued service to BIO-KEY International Inc.

Industry Context

This Form 4 filing reflects a routine insider transaction related to director compensation, common across publicly traded companies. It indicates the company's use of equity-based compensation plans to align director interests with long-term shareholder value, a standard practice in the technology and security industry where BIO-KEY operates.

Comparison to Industry Standards

• The use of restricted stock grants and equity for board fees is a common compensation practice for directors in publicly traded companies, aligning their interests with long-term company performance.
• The vesting schedule of three equal annual installments is a typical structure for restricted stock units, comparable to similar plans seen in small-cap technology companies.
• While specific comparable companies are not mentioned in the filing, this compensation structure is consistent with governance practices observed in companies like Identiv (INVE) or Aware (AWRE), which also operate in identity management and biometrics.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in director ownership through stock grants aligns the director's interests with shareholders, potentially fostering long-term value creation.
• Employees: The 2023 Stock Incentive Plan, under which these shares were granted, may also apply to other employees, indicating a broader equity compensation strategy.

Next Steps

• The 5,000 restricted shares will vest in three equal annual installments on each of the next three anniversaries of the grant date.

Key Dates

Recommendation

Keywords

BIO-KEY International, BKYI, Form 4, Insider Transaction, Stock Grant, Restricted Stock, Director Compensation, Stock Incentive Plan, Beneficial Ownership